GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK confirmed this morning that the disappointing ... The company said it has started the processing for withdrawing the marketing authorisation for Blenrep (belantamab mafodotin) at the request ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...

GSK is "willing to license these patents on commercially reasonable terms and to ensure continued patient access," a company spokesperson said. The lawsuits add to a web of U.S. court cases ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

South African retailer giant Pick n Pay has announced plans to leave Nigeria by selling its stake in A.G. LeventisThe decision comes less than 5 years after it entered the market with so much promise ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over ... entry-level salaries in London, the news website Legal Cheek first reported.

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...